Finn Patrick John sold $9.2M of TWST
Finn Patrick John (President and COO) sold 78,355 shares of Twist Bioscience Corp (TWST) at an average of $117.64 ($115.90–$122.58, $9.22M total) across 7 trades on 2026-08-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider sentiment, which traders may weigh against recent stock performance.
Market read
Primary source insider sale; modest materiality for short‑term traders.
What to watch
No change in company fundamentals disclosed; the insider retains a sizable stake.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan sale by a senior officer is a standard reporting requirement.
Ticker impact
President and COO Finn Patrick John sold 78,355 shares for $9.2M via a 10b5-1 plan, reducing his stake to 214,678 shares.
Potential modest downside pressure over the next few days.
A $9.2M sale by a top executive signals possible concerns, but the sale is pre‑arranged under a 10b5‑1 plan, limiting immediate inference.
Market effects
May raise questions about executive confidence in Twist Bioscience's growth prospects.
Limited to US biotech sector.
Low, confined to Twist Bioscience investors.
Counterpoint
The sale is pre‑arranged; could be routine portfolio rebalancing rather than a negative signal.
Key entities
- IndividualFinn Patrick John
President and COO of Twist Bioscience, reporting officer.
- CompanyTwist Bioscience Corp
Biotech company specializing in DNA synthesis.
